‘’Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine’’ Headache 2024, 64, 243-252.

‘’Efficacy of Dual ENKephalinase Inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors’’ Headache 2023, 63, 621-633.

‘’The inhibition of Enkephalin Catabolism by Dual ENKephalinase Inhibitor: A novel possible therapeutic approach for opioid use disorders’’ Br. J. Pharmacol. 2023, 180, 879-893.

‘’Dual ENKephalinase Inhibitor (DENKI) PL37 as a potential novel acute and preventive treatment of Migraine’’ Brain 2022, 145, 2664-2670.

‘’Process for industrial preparation of the disodium salt of ((2S)-3-([1,1′-biphenyl]-4-yl)-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-L-alanine WO2021/116617.

‘’N-Formylhydroxylamines as Neprilysin (NEP) inhibitors, in particular as mixed inhibitors of aminopeptidase N (APN) and Neprilysin (NEP)’’ WO2021/005294.

‘’Dual enkephalinase inhibitor (DENKI) PL265: a novel topical treatment to alleviate corneal inflammation and ocular pain’’ Pain 2019, 160, 307-321.

‘’Amino acid derivatives containing a disulfanyl group in the form of a NEP and APN inhibitor for the prevention and treatment of trigeminal nerve pain’’ WO2019/145507.

‘’Aminophosphinic derivatives for preventing and treating ocular inflammation’’ WO2018/162860.

‘’Aminophosphinic derivatives for preventing and treating eye pain’’ WO2017/093322.

‘’Substituted α-mercaptoketones, new types of specific neprilysin inhibitors” Bioorg. Med. Chem. Lett. 2017, 3883-3389.

‘’Industrial process of (5S,10S)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (E)-3-carboxyacrylate salt’’ WO2017/064250.

‘’Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain’’ Scand. J. Pain 2017, 14, 25-38.

‘’Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain’’ Eur. J. Pharmacol. 2016, 788, 176-182.

‘’Modulation of Disulfide Dual Enkephalinase Inhibitors (DENKIs) Activity by a Transient N-protection for Pain Alleviation by Oral Route’’ Eur. J. Med. Chem. 2015, 102, 58-67.

‘’Long lasting oral analgesic effects of N-Protected Aminophosphinic Dual ENKephalinase Inhibitors (DENKIs) in peripherally-controlled pain’’ Pharm. Res. Per. 2015, 3, e00116.

‘’New orally active Dual ENKephalinase Inhibitors (DENKIs) for central and peripheral pain treatment’’ »5763″ Med. Chem. 2014, 57, 5748-5763.

‘’Mixed inhibitors of aminopeptidase N and Neprilysin’’ WO2014/064162.

‘’Neprilysin Inhibitors’’ WO2014/064166.

‘’A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity’’ Anal. Biochem. 2013, 441, 152-161.

‘’Comparison of fluorigenic peptide substrates PL50, SNAPtide and BoTest A/E for BoNT/A detection and quantification: exosite binding confers high assay sensitivity’’ J. Biomol. Screen. 2013, 18, 726-735.

‘’A highly sensitive fluorescent quenched substrate of the Legionella Major Secretory Protein (Msp) based on its structural analysis’’ J. Biol. Chem. 2012, 287, 20221-20230.

‘’Novel substrates the fluorescence of which is suppressed, preparation thereof, for identifying, detecting, and assaying Legionella Pneumophila’’ WO2012/010668.

‘’Agents for the molecular imaging of serine-protease in human pathologies’’ WO2012/072819.

‘’Pluripotentialities of a quenched fluorescent peptide substrate library: enzymatic detection, characterization, and isoenzymes differentiation’’ Anal. Biochem. 2011, 419, 95-105.

‘’Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in Vitro and ex Vivo enzymatic assay’’ J. Biol. Chem. 2010, 285, 34390-34400.

‘’Aminophosphinic derivatives that can be used in the treatment of pain’’ WO2010/010106.

‘’Structure of aminopeptidase N from Escherichia coli complexed with the transition-state analogue aminophosphinic inhibitor PL250’’ Acta Crystallogr., Sect. D: Biol. Crystallogr. 2009, D65, 814-822.

‘’Detection and quantification of botulinum neurotoxin type A by a novel rapid in vitro fluorimetric assay’’ Appl. Env. Microbiol. 2009, 75, 4382-4390.

‘’Novel amino acid derivatives, method for preparing same, and therapeutic use thereof’’ WO2009/138436.

‘’Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentialisation by gabapentin’’ Eur. J. Pharmacol. 2008, 596, 50-55.

‘’Vasopeptidases inhibitors of ACE, NEP and ECE’’ PharmaChem 2004, 3, 41-45.

‘’In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P’2 position’’ J. Pept. Res. 2004, 63, 99-107.

‘’N-[2-(indan-1-yl)-3-mercapto-propionylamino] derivatives of the α-aminoacids as highly potent inhibitors of the three vasopeptidases. In vitro and in vivo activities’’ Bioorg. Med. Chem. Lett. 2002, 12, 2001-2005.

‘’Towards an optimal joint recognition of the S’1 subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP)’’ J. Med. Chem. 2002, 45, 1477-1486.

‘’Amino acid derivatives and use thereof as NEP, ACE and ECE inhibitors’’ WO2001/060822.

‘’Stereospecific nucleophilic substitution of optically active 1-benzyloxy-2,2,2-trifluoroethyl tosylate with lithium tetraalkylaluminates prepared by Ti-catalyzed hydroalumination of olefins’’ Synlett 1998, 1353-1354.

‘’Nucleophilic substitution of optically active 1-Alkoxy(polyfluoro)alkyl sulfonate’’ Chem. Commun. 1998, 1259-1260.

‘’Asymmetric Synthesis of 1-Alkoxy-2,2,2-Trifluoroethanol Derivatives’’ Chem. Lett. 1998, 665-666.

‘’Synthesis and In Vitro Antibacterial Activity of Catechol-Spiramycin Conjugates’’ J. Antibiotics 1998, 51, 786-794.

‘’Easy access to some chiral 2- or 3-substitued 1-indanones and 3,4-dihydrocoumarins’’ Chemistry and Industry 1993, 206-208.